Missed NVDA?
Don’t Miss the Next One.
Join 5,000+ investors using Ticker Nerd’s Market Radar to stay ahead of major market moves, analyst upgrades, and trending opportunities — for free.
NVCT Stock Forecast 2026-2027
$19.14
Current Price
$586.37M
Market Cap
Buy 5
Hold 0
Sell 0
Wall St Analyst Ratings
Distance to NVCT Price Targets
+103.8%
To High Target of $39.00
+72.4%
To Median Target of $33.00
+14.9%
To Low Target of $22.00
NVCT Price Momentum
+4.3%
1 Week Change
+38.5%
1 Month Change
+145.4%
1 Year Change
+153.5%
Year-to-Date Change
-34.6%
From 52W High of $29.28
+244.9%
From 52W Low of $5.55
📊 TOP ANALYST CALLS
Did NVCT Make This Month's Elite Buy List?
We don't follow just any analyst — only the top 3% with a proven track record make our cut. See if Nuvectis Pharma is one of their latest high-conviction picks.
Latest NVCT Stock Price Targets & Analyst Predictions
Based on our analysis of 2 Wall Street analysts, NVCT has a bullish consensus with a median price target of $33.00 (ranging from $22.00 to $39.00). The overall analyst rating is Strong Buy (9.2/10). Currently trading at $19.14, the median forecast implies a 72.4% upside. This outlook is supported by 5 Buy, 0 Hold, and 0 Sell ratings.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
NVCT Analyst Ratings
5
Buy
0
Hold
0
Sell
NVCT Price Target Range
Low
$22.00
Average
$33.00
High
$39.00
Current: $19.14
Latest NVCT Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for NVCT.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| Jul 6, 2026 | Roth Capital | Jonathan Aschoff | Buy | Maintains | $33.00 |
| Jun 22, 2026 | HC Wainwright & Co. | Buy | Maintains | $N/A | |
| Jun 12, 2026 | HC Wainwright & Co. | Buy | Maintains | $N/A | |
| Aug 4, 2025 | HC Wainwright & Co. | Buy | Maintains | $N/A | |
| Apr 30, 2025 | HC Wainwright & Co. | Buy | Reiterates | $N/A | |
| Apr 2, 2025 | Maxim Group | Buy | Initiates | $N/A | |
| Mar 17, 2025 | Laidlaw & Co. | Buy | Initiates | $N/A | |
| Feb 25, 2025 | HC Wainwright & Co. | Buy | Maintains | $N/A | |
| Aug 6, 2024 | HC Wainwright & Co. | Buy | Reiterates | $N/A | |
| May 8, 2024 | HC Wainwright & Co. | Buy | Reiterates | $N/A | |
| Sep 15, 2023 | HC Wainwright & Co. | Buy | Reiterates | $N/A | |
| Mar 7, 2023 | HC Wainwright & Co. | Buy | Reiterates | $N/A | |
| Feb 10, 2023 | HC Wainwright & Co. | Buy | Reiterates | $N/A | |
| Jul 13, 2022 | Ladenburg Thalmann | Buy | Initiates | $N/A | |
| May 10, 2022 | HC Wainwright & Co. | Buy | Maintains | $N/A | |
| Mar 2, 2022 | HC Wainwright & Co. | Buy | Initiates | $N/A |
Nuvectis Pharma Inc. (NVCT) Competitors
The following stocks are similar to Nuvectis Pharma based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
Nuvectis Pharma Inc. (NVCT) Financial Data
Nuvectis Pharma Inc. has a market capitalization of $586.37M with a P/E ratio of -14.1x. The company generates $0 in trailing twelve-month revenue with a 0.0% profit margin.
Revenue growth is N/A quarter-over-quarter, while maintaining an operating margin of 0.0% and return on equity of -154.4%.
Valuation Metrics
Market Cap
$586.37M
Enterprise Value
$460.02M
P/E Ratio
-14.1x
PEG Ratio
3.8x
Price/Sales
N/A
Growth & Margins
Revenue Growth (YoY)
N/A
Gross Margin
N/A
Operating Margin
0.0%
Net Margin
0.0%
EPS Growth
N/A
Financial Health
Cash/Price Ratio
+4.9%
Current Ratio
2.3x
Debt/Equity
0.0x
ROE
-154.4%
ROA
-63.6%
💡 SKIP THE NOISE
97% of Analyst Ratings Go Nowhere
We filter thousands of calls to find the few that actually matter. Get the top analyst buy ratings — tracked and updated every Monday and Thursday.
Nuvectis Pharma Inc. (NVCT) Business Model
About Nuvectis Pharma Inc.
What They Do
Develops innovative cancer treatments.
Business Model
Nuvectis Pharma Inc. generates revenue by developing and commercializing proprietary cancer therapies. The company advances its compounds through clinical trials, which can lead to partnerships, licensing agreements, or sales of successful therapies to healthcare providers and pharmaceutical companies.
Additional Information
Nuvectis is focused on addressing significant unmet medical needs in oncology and collaborates with research institutions to enhance its research capabilities. The company's efforts contribute to the broader biopharmaceutical innovation landscape and attract interest from investors looking for advancements in cancer treatments.
Company Information
Sector
Healthcare
Industry
Biotechnology
Employees
12
CEO
Mr. Ron Bentsur M.B.A.
Country
United States
IPO Year
2021
Website
www.nuvectis.comNuvectis Pharma Inc. (NVCT) Latest News & Analysis
Latest News
Quick Summary
Nuvectis Pharma (NASDAQ: NVCT) is transitioning to a late-stage rare-disease focus after licensing NXP100 for PNH and NXP200 from Haisco, securing worldwide rights outside China.
Why It Matters
Nuvectis Pharma's transition to rare diseases and acquisition of NXP100 could diversify revenue streams and enhance growth potential, impacting its stock performance and investor sentiment.
Source: Newsfile Corp
Market Sentiment:
Neutral
Wall Street Analysts See a 61.46% Upside in Nuvectis Pharma (NVCT): Can the Stock Really Move This High?
10 days ago
Quick Summary
Nuvectis Pharma (NVCT) has a consensus price target suggesting a 61.5% upside. Upward revisions in earnings estimates may indicate potential near-term gains.
Why It Matters
The 61.5% upside potential suggests significant growth for Nuvectis Pharma, while positive earnings estimate revisions indicate increasing investor confidence and potential stock appreciation.
Source: Zacks Investment Research
Market Sentiment:
Positive
Quick Summary
Nuvectis Pharma (Nasdaq: NVCT) has launched an underwritten public offering of its common stock, with a potential 30-day option for underwriters to purchase an additional 15%.
Why It Matters
Nuvectis Pharma's public offering may dilute existing shares, impacting stock value. It highlights the company's funding efforts for growth in clinical-stage therapies, affecting investor sentiment.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Quick Summary
Nuvectis Pharma priced its public offering of 5 million shares at $20 each, aiming for $100 million in gross proceeds. The offering closes around July 1, 2026, pending conditions.
Why It Matters
Nuvectis Pharma's $100 million stock offering can dilute existing shares but also signals confidence in funding future innovations, impacting stock valuation and investor sentiment.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Quick Summary
Nuvectis Pharma, Inc. (NVCT) is under evaluation for its potential as a top stock pick for momentum investors. Further analysis is needed to determine its viability.
Why It Matters
Nuvectis Pharma's potential as a top stock pick indicates strong investor interest, which could drive share price volatility and attract momentum traders seeking quick gains.
Source: Zacks Investment Research
Market Sentiment:
Positive
Quick Summary
Nuvectis Pharma (NVCT) has been upgraded to a Zacks Rank #2 (Buy), indicating improved earnings outlook and potential for stock price increase.
Why It Matters
Nuvectis Pharma's Zacks Rank upgrade to #2 signals increased confidence in its earnings potential, likely leading to a stock price increase and attracting investor interest.
Source: Zacks Investment Research
Market Sentiment:
Positive
Frequently Asked Questions About NVCT Stock
What is Nuvectis Pharma Inc.'s (NVCT) stock forecast for 2027?
Based on our analysis of 2 Wall Street analysts, Nuvectis Pharma Inc. (NVCT) has a median price target of $33.00. The highest price target is $39.00 and the lowest is $22.00.
Is NVCT stock a good investment in 2027?
According to current analyst ratings, NVCT has 5 Buy ratings, 0 Hold ratings, and 0 Sell ratings. The stock is currently trading at $19.14. Always conduct your own research and consider your investment goals before making investment decisions.
What is the long-term price prediction for NVCT stock?
Wall Street analysts predict NVCT stock could reach $33.00 in the next 12 months. This represents a 72.4% increase from the current price of $19.14. Please note that this is a projection by Wall Street analysts and not a guarantee.
What is Nuvectis Pharma Inc.'s business model?
Nuvectis Pharma Inc. generates revenue by developing and commercializing proprietary cancer therapies. The company advances its compounds through clinical trials, which can lead to partnerships, licensing agreements, or sales of successful therapies to healthcare providers and pharmaceutical companies.
What is the highest forecasted price for NVCT Nuvectis Pharma Inc.?
The highest price target for NVCT is $39.00 from at , which represents a 103.8% increase from the current price of $19.14.
What is the lowest forecasted price for NVCT Nuvectis Pharma Inc.?
The lowest price target for NVCT is $22.00 from at , which represents a 14.9% increase from the current price of $19.14.
What is the overall NVCT consensus from analysts for Nuvectis Pharma Inc.?
The overall analyst consensus for NVCT is bullish. Out of 2 Wall Street analysts, 5 rate it as Buy, 0 as Hold, and 0 as Sell, with a median price target of $33.00.
How accurate are NVCT stock price projections?
Stock price projections, including those for Nuvectis Pharma Inc., are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
Important Disclaimer
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
Last updated: July 18, 2026 2:45 AM UTC